Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.36 |
| ▸ | PDE1A | P54750 | 4/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.36 |
| ▸ | PDE9A | O76083 | 8/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4560602 | 0.84 | PDE1C (0.40) | LRRK2PDE1CPDE1APDE1BPDE9A | |
| SCHEMBL16975528 | 0.84 | PKM (0.34) | MAPTALDH1A1LMNA | |
| SCHEMBL20555375 | 0.81 | PDE1C (0.42) | LRRK2PDE1CPDE1APDE1BPDE9A | |
| SCHEMBL16985266 | 0.77 | TXNRD1 (0.43) | PDE1CPDE1APDE1BCYP1A2CYP2C9 | |
| SCHEMBL25420038 | 0.77 | ALDH1A1 (0.39) | LRRK2PDE1CPDE1APDE1BCYP1A2 | |
| SCHEMBL31121567 | 0.76 | PDE1C (0.41) | LRRK2PDE1CPDE1APDE1BPDE9A | |
| SCHEMBL16985290 | 0.75 | LRRK2 (0.39) | LRRK2PDE1CPDE1APDE1BPDE9A | |
| SCHEMBL30896408 | 0.75 | PIK3CD (0.39) | LRRK2PDE1CPDE1APDE1BPDE9A | |
| SCHEMBL16975516 | 0.74 | ALDH1A1 (0.41) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL28434366 | 0.73 | MEN1 (0.40) | CYP1A2CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | LRRK2 1/4885PDE1C 2985/4885PDE1A 2561/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885PDE1C 3722/4885PDE1A 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.